6.
Wijsenbeek M
. Progress in the treatment of pulmonary fibrosis. Lancet Respir Med. 2020; 8(5):424-425.
DOI: 10.1016/S2213-2600(20)30062-X.
View
7.
Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells C
. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019; 35(11):2015-2024.
DOI: 10.1080/03007995.2019.1647040.
View
8.
Raghu G
. Idiopathic pulmonary fibrosis: shifting the concept to irreversible pulmonary fibrosis of many entities. Lancet Respir Med. 2019; 7(11):926-929.
DOI: 10.1016/S2213-2600(19)30311-X.
View
9.
Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K
. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824.
PMC: 5450933.
DOI: 10.1164/rccm.2009-040GL.
View
10.
Pope J, Denton C, Johnson S, Fernandez-Codina A, Hudson M, Nevskaya T
. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023; 19(4):212-226.
PMC: 9970138.
DOI: 10.1038/s41584-023-00909-5.
View
11.
Cui F, Sun Y, Xie J, Li D, Wu M, Song L
. Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis. Eur Respir J. 2022; 61(2).
DOI: 10.1183/13993003.00777-2022.
View
12.
Yue D, Zhang Q, Zhang J, Liu W, Chen L, Wang M
. Diesel exhaust PM2.5 greatly deteriorates fibrosis process in pre-existing pulmonary fibrosis via ferroptosis. Environ Int. 2022; 171:107706.
DOI: 10.1016/j.envint.2022.107706.
View
13.
Zhang T, Zhang J, Lv C, Li H, Song X
. Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment. Front Pharmacol. 2022; 13:1059434.
PMC: 9705785.
DOI: 10.3389/fphar.2022.1059434.
View
14.
Meyerholz D
. Rigid respiration: fulminant pulmonary fibrosis after COVID-19. EBioMedicine. 2022; 87:104428.
PMC: 9792276.
DOI: 10.1016/j.ebiom.2022.104428.
View
15.
Bailey J, Sala M
. The Pandemic within the Pandemic: Predicting Pulmonary Fibrosis after COVID-19. Am J Respir Cell Mol Biol. 2023; 69(3):253-254.
PMC: 10503304.
DOI: 10.1165/rcmb.2023-0167ED.
View
16.
Valenzuela C, Torrisi S, Kahn N, Quaresma M, Stowasser S, Kreuter M
. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. Respir Res. 2020; 21(1):7.
PMC: 6945404.
DOI: 10.1186/s12931-019-1269-6.
View
17.
King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M
. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92.
DOI: 10.1056/NEJMoa1402582.
View
18.
George P, Patterson C, Reed A, Thillai M
. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019; 7(3):271-282.
DOI: 10.1016/S2213-2600(18)30502-2.
View
19.
Liu C, Chen L
. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022; 185(12):2016-2034.
DOI: 10.1016/j.cell.2022.04.021.
View
20.
Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G
. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022; 348:84-94.
PMC: 9644292.
DOI: 10.1016/j.jconrel.2022.05.043.
View